Menu
Back to Journals » Drug Design, Development and Therapy » Volume 11
Gut microbiota–derived short-chain fatty acids and kidney diseases
Authors Li L, Ma L, Fu P
Received 5 September 2017
Accepted for publication 8 November 2017
Published 11 December 2017 Volume 2017:11 Pages 3531—3542
DOI https://doi.org/10.2147/DDDT.S150825
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Anastasios Lymperopoulos
Lingzhi Li, Liang Ma, Ping Fu
Kidney Research Institute, Department of Nephrology, West China Hospital of Sichuan University, Chengdu 610041, China
Abstract: Gut microbiota and its metabolites play pivotal roles in host physiology and pathology. Short-chain fatty acids (SCFAs), as a group of metabolites, exert positive regulatory effects on energy metabolism, hormone secretion, immune inflammation, hypertension, and cancer. The functions of SCFAs are related to their activation of transmembrane G protein-coupled receptors and their inhibition of histone acetylation. Though controversial, growing evidence suggests that SCFAs, which regulate inflammation, oxidative stress, and fibrosis, have been involved in kidney disease through the activation of the gut–kidney axis; however, the molecular relationship among gut microbiota–derived metabolites, signaling pathways, and kidney disease remains to be elucidated. This review will provide an overview of the physiology and functions of SCFAs in kidney disease.
Keywords: gut microbiome, short-chain fatty acids, kidney diseases, gut–kidney axis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.